
# CARDIOVASCULAR RISK REDUCTION IN T2DM:

# Applying the Trial Data to Clinical Practice



- Deepak L. Bhatt MD MPH
- Lawrence Blonde MD
   Harold Bays MD


Jointly provided by Cardiometabolic
Health Congress and Global Education
Group

tions when individualiz-

ing therapy for patients with T2DM and CVD



### THE BIG PICTURE









Diabetes Patients have 2-4X increased risk for heart disease morbidity and mortality



280,000 heart attacks annually

#### GAP



Limited strategies to address cardiovascular risk-strict glycemic control not sufficient

## **CVOTS: A SURPRISING SOLUTION?**



A Paradigm Shift in T2DM Management: From Glucose To Cardiovascular Outcomes:

### **BUT ANOTHER GAP...**



More than 20 trials and counting...
What do they mean?
How can we 'translate' them and get over the confusion?

# WHAT CLINICIANS NEED TO KNOW



Be aware of the prevalence and burden of cardiovascular comorbidities in patients with T2D





Understand the data behind practice-changing



Interpret and apply the data to patient care

#### THE INTERVENTION **MULTI-MODAL INFOGRAPHIC ACTIVITIES:** DIDACTIC LECTURES, CASE-BASED PRESENTATIONS Live Satellite Symposium -**Enduring Online Activity** CMHC Annual October 2018 Launched January 19, 2019 **€** Individualization of **CVOT Data in Your CV Comorbidities in Review of Recent CVOT** Results and **T2DM Patients** Treatment in T2DM Clinical Practice: Patients with CVD **Patient Case Clinical Implications**








and GLP-1 RAs for

treatment of T2DM

patients with CVD







More trials coming out, more education needed



Potential mechanisms of action, specific populations, patients without T2DM or existing CVD

# REFERENCES

Das, Sandeep R., et al. "2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways." Journal of the American College of Cardiology

Hinnen, Deborah, and Davida F. Kruger. "Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials."

Diabetes, metabolic syndrome and obesity: targets and therapy 12

The activities in this program were jointly provided by Cardiometabolic Health Congress and Global Education Group.

Supported by educational grants from Astrazeneca and Novo Nordisk. Scan the QR code to access a PDF of this poster online and supplementary program and outcomes measurement information.

